UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Certain graphics on this page may be affected by ad-blocking software. If portions of the page appear blank and an ad blocker is enabled, please disable the ad blocker and refresh the page to ensure ...